ANXA1 and obesity due to melanocortin 4 receptor deficiency: Peripherally, ANXA1 may act in an endocrine manner to regulate inflammatory biomarkers to dampen inflammation, regulate insulin secretion and improve the metabolic profile to reduce the risk of developing obesity associated co-morbidities.